Latest Regulatory Decisions News

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.

Berkeley Energia reports promising metallurgical results from its Conchas critical minerals project in Spain while pursuing a US$1 billion arbitration over permitting delays at its Salamanca uranium project.

The Takeovers Panel has declined to investigate allegations of undisclosed shareholder associations at Cyclone Metals, following a contentious director removal. This decision signals regulatory confidence in the company’s governance stability.

Manuka Resources is gearing up to recommence gold and silver production in the Cobar Basin by mid-2026 while awaiting a pivotal regulatory decision on its large-scale iron sands project in New Zealand.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

The Takeovers Panel has declined to find unacceptable circumstances in Emu NL’s recent placement before its AGM, ruling no control effect was evident. This decision underscores regulatory caution around capital raises near board votes.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Iris Cairns Property Pty Ltd has announced a delay in its takeover bid for Reef Casino Trust due to extended regulatory approval timelines, signaling a planned extension of the offer period beyond May 2026.

Reef Casino Trust’s takeover bid by Iris Cairns Property faces a regulatory hurdle as Queensland’s Office of Liquor and Gaming Regulation delays suitability investigations, pushing the offer period beyond March 2026.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Icon Energy Limited holds steady with $294,000 cash as it awaits key regulatory decisions on ATP 855 renewal and Petroleum Lease PL-1144, facing a looming ASX suspension deadline.

St Barbara Limited reports steady progress on its Simberi Expansion Project in Papua New Guinea and Atlantic Gold Projects in Canada, despite production challenges and pending regulatory decisions. A recent A$58 million capital raise strengthens its financial position for growth.